Characteristics of patients with cancer receiving dupilumab for ircAEs
| All patients (n=39) | Responders to dupilumab (n=34) | Non-responders to dupilumab (n=5) | P value | ||
| Age | Mean (SD) | 68.1 (12.4) | 69.4 (11.3) | 59.8 (17.8) | 0.11 |
| n (%) | n (%) | n (%) | |||
| Sex | Female | 18 (46.2) | 15 (44.1) | 3 (60.0) | 0.51 |
| Male | 21 (53.8) | 19 (55.9) | 2 (40.0) | ||
| Race | White | 32 (82.1) | 27 (79.4) | 5 (100.0) | 0.53 |
| Asian/Indian | 5 (12.8) | 5 (14.7) | 0 (0) | ||
| Other | 2 (5.1) | 2 (5.9) | 0 (0) | ||
| Ethnicity | Hispanic or Latino | 3 (7.7) | 3 (8.8) | 0 (0) | 0.49 |
| Non-Hispanic | 36 (92.3) | 31 (91.2) | 5 (100.0) | ||
| Cancer history | Melanoma/skin cancers | 8 (20.5) | 6 (17.7) | 2 (40) | 0.762 |
| HNSCC | 4 (10.3) | 4 (11.8) | 0 (0) | ||
| Lung | 6 (15.4) | 5 (14.7) | 1 (20) | ||
| Sarcoma | 4 (10.3) | 3 (8.8) | 1 (20) | ||
| Urothelial/RCC | 10 (25.6) | 9 (26.5) | 1 (20) | ||
| Gynecologic | 3 (7.7) | 3 (8.8) | 0 (0) | ||
| Gastrointestinal | 4 (10.3) | 4 (11.8) | 0 (0) | ||
| ICI type | Pembrolizumab | 16 (41) | 16 (47.1) | 0 (0) | 0.179 |
| Nivolumab | 13 (33.3) | 10 (29.4) | 3 (60) | ||
| Ipilimumab/nivolumab | 5 (12.8) | 3 (8.8) | 2 (40) | ||
| Atezolizumab | 3 (7.7) | 3 (8.8) | 0 (0) | ||
| Avelumab | 1 (2.6) | 1 (2.9) | 0 (0) | ||
| Ipilimumab | 1 (2.6) | 1 (2.9) | 0 (0) |
HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitors; ircAEs, immune-related cutaneous adverse events; RCC, renal cell carcinoma.